{
  "consolidation_metadata": {
    "timestamp": "2025-09-08T09:09:22.963011",
    "indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
    "consolidation_type": "picos",
    "total_consolidated_picos": 15,
    "source_countries": [
      "DE",
      "DK",
      "EN",
      "FR",
      "NL",
      "PO",
      "PT",
      "SE"
    ],
    "source_types": [
      "clinical_guideline",
      "hta_submission"
    ]
  },
  "consolidated_picos": [
    {
      "Population": "Adult patients with advanced or metastatic non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior systemic therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "adagrasib",
      "Countries": [
        "DK",
        "FR"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "patients with active KRAS G12C and 0-2 performance status and previously treated with platinum-based chemotherapy and immunotherapy (where applicable)",
        "adult patients with advanced non-small cell adagrasib bronchial cancer (ASBC) with KRAS G12C mutation, whose disease has progressed after at least one prior systemic therapy"
      ],
      "Original_Comparator_Variants": [
        "adagrasib"
      ]
    },
    {
      "Population": "Adult patients with advanced or metastatic non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior systemic therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "atezolizumab",
      "Countries": [
        "DE",
        "PT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
        "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy"
      ],
      "Original_Comparator_Variants": [
        "atezolizumab"
      ]
    },
    {
      "Population": "Adult patients with advanced or metastatic non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior systemic therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "chemotherapy",
      "Countries": [
        "NL"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "patients with non–smallcell lung cancer stage IIIB/IV and a KRAS G12C mutation"
      ],
      "Original_Comparator_Variants": [
        "chemotherapy"
      ]
    },
    {
      "Population": "Adult patients with advanced or metastatic non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior systemic therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "docetaxel",
      "Countries": [
        "DE",
        "DK",
        "EN",
        "NL",
        "PT"
      ],
      "Source_Types": [
        "clinical_guideline",
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
        "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
        "patients with non–small-cell lung cancer stage IIIB/IV and a KRAS G12C mutation",
        "patients with advanced NSCLC and KRAS G12C mutation previously treated with platinum-based chemotherapy and immunotherapy",
        "KRAS G12C mutation-positive locally advanced or metastatic non-small-cell lung cancer in adults whose disease has progressed on, or who cannot tolerate, platinum-based chemotherapy or anti-PD-1/PD-L1 immunotherapy"
      ],
      "Original_Comparator_Variants": [
        "docetaxel"
      ]
    },
    {
      "Population": "Adult patients with advanced or metastatic non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior systemic therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "docetaxel + nintedanib",
      "Countries": [
        "DE",
        "EN",
        "PT"
      ],
      "Source_Types": [
        "clinical_guideline",
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
        "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
        "KRAS G12C mutation-positive locally advanced or metastatic non-small-cell lung cancer in adults whose disease has progressed on, or who cannot tolerate, platinum-based chemotherapy or anti-PD-1/PD-L1 immunotherapy",
        "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy and PD-L1 negative tumours and adenocarcinoma histology"
      ],
      "Original_Comparator_Variants": [
        "docetaxel + nintedanib",
        "docetaxel in combination with nintedanib",
        "docetaxel plus nintedanib"
      ]
    },
    {
      "Population": "Adult patients with advanced or metastatic non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior systemic therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "immunotherapy monotherapy",
      "Countries": [
        "DK"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "patients with oncogene-driven NSCLC treated with immunotherapy alone"
      ],
      "Original_Comparator_Variants": [
        "immunotherapy monotherapy"
      ]
    },
    {
      "Population": "Adult patients with advanced or metastatic non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior systemic therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "nivolumab",
      "Countries": [
        "DE",
        "PT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
        "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy"
      ],
      "Original_Comparator_Variants": [
        "nivolumab"
      ]
    },
    {
      "Population": "Adult patients with advanced or metastatic non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior systemic therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "pemetrexed",
      "Countries": [
        "DE",
        "PT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
        "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy"
      ],
      "Original_Comparator_Variants": [
        "pemetrexed"
      ]
    },
    {
      "Population": "Adult patients with advanced or metastatic non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior systemic therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "pembrolizumab",
      "Countries": [
        "DE",
        "PT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
        "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy"
      ],
      "Original_Comparator_Variants": [
        "pembrolizumab"
      ]
    },
    {
      "Population": "Adult patients with advanced or metastatic non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior systemic therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "platinum doublet",
      "Countries": [
        "PT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy"
      ],
      "Original_Comparator_Variants": [
        "platinum doublet"
      ]
    },
    {
      "Population": "Adult patients with advanced or metastatic non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior systemic therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sotorasib",
      "Countries": [
        "DK",
        "DE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "patients with active KRAS G12C and 0-2 performance status and previously treated with platinum-based chemotherapy and immunotherapy (where applicable)",
        "Patients with Stage IV NSCLC with a KRAS-G12C mutation and failure of at least one systemic therapy"
      ],
      "Original_Comparator_Variants": [
        "sotorasib",
        "currently approved (02/22) Sotorasib"
      ]
    },
    {
      "Population": "Adult patients with advanced or metastatic non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior systemic therapy and tumours expressing PD-L1 with a TPS >=1%",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "pembrolizumab",
      "Countries": [
        "DE",
        "PT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy and tumours expressing PD-L1 with a TPS >=1%",
        "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy and PD-L1 expressing tumours (PD-L1 expression ≥ 1% of tumour cells)"
      ],
      "Original_Comparator_Variants": [
        "pembrolizumab"
      ]
    },
    {
      "Population": "Adult patients with advanced or metastatic non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior systemic therapy and PD-L1 negative tumours",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "docetaxel",
      "Countries": [
        "DE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy and PD-L1 negative tumours"
      ],
      "Original_Comparator_Variants": [
        "docetaxel"
      ]
    },
    {
      "Population": "Adult patients with advanced or metastatic non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior systemic therapy and PD-L1 negative tumours",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "pemetrexed",
      "Countries": [
        "DE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy and PD-L1 negative tumours"
      ],
      "Original_Comparator_Variants": [
        "pemetrexed"
      ]
    },
    {
      "Population": "KRAS G12C mutation-positive locally advanced or metastatic non-small-cell lung cancer in adults whose disease has progressed on, or who cannot tolerate, platinum-based chemotherapy or anti-PD-1/PD-L1 immunotherapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "",
      "Countries": [
        "PO",
        "SE"
      ],
      "Source_Types": [
        "hta_submission",
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context"
      ],
      "Original_Comparator_Variants": [
        ""
      ]
    }
  ]
}